Skip to main content
Skip to main content
Back to Grand Rounds
Grand RoundsWeekly Evidence Brief

Sleep Medicine

Edition

30-Second Takeaway

  • Rising AHI in men predicts higher MACCE risk, and apparent OSA remission may not normalize cardiovascular risk.
  • GLP-1 and dual agonists markedly reduce incident sleep apnea and adverse outcomes in obesity and type 2 diabetes.
  • COPD–OSA overlap on home NIV has better survival than COPD alone, highlighting the importance of OSA detection.
  • Bronchiectasis patients have very high PSG-confirmed OSA prevalence despite non-obese phenotype, warranting proactive screening.
  • Dry-EEG wearables and VR are emerging tools for objective sleep assessment and behavioral insomnia treatment.

Week ending April 4, 2026

Dynamic OSA risk, incretin therapies, and emerging tools reshaping sleep medicine

Dynamic OSA status in men predicts MACCE despite apparent remission

PULMONOLOGYMar 30, 2026

In this SHHS cohort, 2,653 participants had two PSGs about five years apart, with OSA defined as AHI ≥15/h. About 20% of initially non-OSA participants developed OSA, while roughly one-third with OSA reverted to non-OSA. In men, transition to OSA, remission from OSA, or stable OSA all increased MACCE risk versus stable non-OSA. AHI gain predicted higher MACCE and mortality in men, whereas no significant associations were seen in women.

Semaglutide reduces new-onset OSA and cardiorenal events in obesity

ANNALS OF THE AMERICAN THORACIC SOCIETYMar 31, 2026

This TriNetX study compared semaglutide users with matched controls in obesity cohorts with and without baseline OSA. In obesity without OSA, semaglutide was associated with lower incident OSA (HR 0.62; 95% CI 0.60–0.63). In obesity with OSA, semaglutide reduced a composite of mortality, MACE, and MAKE (HR 0.72; 95% CI 0.66–0.78). All-cause mortality, MACE, and MAKE were each significantly lower, supporting semaglutide as disease-modifying in obesity-related OSA.

COPD–OSA overlap on domiciliary NIV has lower mortality

ANNALS OF THE AMERICAN THORACIC SOCIETYMar 31, 2026

This French national cohort included 54,545 COPD patients ≥40 years initiated on home NIV for hypercapnic respiratory failure. Multistate models compared transitions between stable, severe exacerbation, and death for overlap syndrome versus COPD without OSA. Overlap patients had lower probabilities of death from both stable and severe exacerbation states than COPD-only patients. They were more likely to recover from severe exacerbations, and overall mortality after NIV initiation was 33% lower in overlap syndrome.

References

Numbered in order of appearance. Click any reference to view details.

Additional Reads

Optional additional studies from this edition.

Edition context

Clinical signal

  • OSA burden is dynamic over time, and longitudinal AHI trajectories, especially in men, have major cardiovascular implications.
  • Incretin-based weight-loss pharmacotherapy appears to reduce both new-onset sleep apnea and downstream cardiometabolic events.
  • Overlap syndrome patients on domiciliary NIV show a more favorable mortality trajectory, suggesting a distinct responsive phenotype.